Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2092 entries
Sorted by: Best Match Show Resources per page
… . Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg/Freie Universitaet Berlin, Germany (2) and Graduate Research Training Program PharMetrX (3) Dept …

Graduate training programs stem

[No authors listed]
GSID: R8quIcNZFU8J
V Nock - page-meeting.org

… In a clinical study 17 patients received a combination therapy of carboplatin (C), etoposide (E) and thiotepa (T) including a stem cell rescue consisting of peripheral blood stem cell …

Cite
Nock, V. Leukopenia following triple high-dose chemotherapy and stem cell rescue V. Nock (1, 2), A. Lindauer (3), U. Jaehde (3), C. Kloft (1)(1) Dept. Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg/Freie Universitaet Berlin, Germany (2) and Graduate Research Training Program PharMetrX (3) Dept. Clinical Pharmacy, University of Bonn, Bonn, Germany.
Nock, Valerie. "Leukopenia following triple high-dose chemotherapy and stem cell rescue V. Nock (1, 2), A. Lindauer (3), U. Jaehde (3), C. Kloft (1)(1) Dept. Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg/Freie Universitaet Berlin, Germany (2) and Graduate Research Training Program PharMetrX (3) Dept. Clinical Pharmacy, University of Bonn, Bonn, Germany."
Copy Download .nbib Format: MLA
Regression of metastatic colon tumour from primary adenocarcinoma of the lung due to fistulisation to the bowel lumen.

Ecancermedicalscience

Iwamuro M, Miyabe Y, Hanae K, Yoshinari K, Katsuyoshi T, Murakami T, Hirofumi M, Yamamoto K.
PMID: 24834113
Ecancermedicalscience. 2014 Mar 20;8:412. doi: 10.3332/ecancer.2014.412. eCollection 2014.

An 80-year-old Japanese male was diagnosed with pulmonary adenocarcinoma. The patient exhibited extensive extra pulmonary involvement in the bone, adrenal gland, abdominal lymph nodes, and sigmoid colon. A single course of chemotherapy with carboplatin and pemetrexed was administered as...

Cite
Iwamuro M, Miyabe Y, Hanae K, et al. Regression of metastatic colon tumour from primary adenocarcinoma of the lung due to fistulisation to the bowel lumen. Ecancermedicalscience. 2014;8:412doi: 10.3332/ecancer.2014.412.
Iwamuro, M., Miyabe, Y., Hanae, K., Yoshinari, K., Katsuyoshi, T., Murakami, T., Hirofumi, M., & Yamamoto, K. (2014). Regression of metastatic colon tumour from primary adenocarcinoma of the lung due to fistulisation to the bowel lumen. Ecancermedicalscience, 8412. https://doi.org/10.3332/ecancer.2014.412
Iwamuro, Masaya, et al. "Regression of metastatic colon tumour from primary adenocarcinoma of the lung due to fistulisation to the bowel lumen." Ecancermedicalscience vol. 8 (2014): 412. doi: https://doi.org/10.3332/ecancer.2014.412
Iwamuro M, Miyabe Y, Hanae K, Yoshinari K, Katsuyoshi T, Murakami T, Hirofumi M, Yamamoto K. Regression of metastatic colon tumour from primary adenocarcinoma of the lung due to fistulisation to the bowel lumen. Ecancermedicalscience. 2014 Mar 20;8:412. doi: 10.3332/ecancer.2014.412. eCollection 2014. PMID: 24834113; PMCID: PMC3971873.
Copy Download .nbib Format: NLM
Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

OncoTargets and therapy

Chen D, Cheng J, Yang K, Ma Y, Yang F.
PMID: 24187501
Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013.

BACKGROUND: Chronomodulated chemotherapy has emerged as a new therapy as a result of recent studies focusing on the biological clock. It has been demonstrated that combination chronomodulated chemotherapy of platinum-based drugs and 5-fluorouracil (5-Fu) can significantly improve efficacy and...

Cite
Chen D, Cheng J, Yang K, et al. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013;6:1507-14doi: 10.2147/OTT.S53098.
Chen, D., Cheng, J., Yang, K., Ma, Y., & Yang, F. (2013). Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. OncoTargets and therapy, 61507-14. https://doi.org/10.2147/OTT.S53098
Chen, Dan, et al. "Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma." OncoTargets and therapy vol. 6 (2013): 1507-14. doi: https://doi.org/10.2147/OTT.S53098
Chen D, Cheng J, Yang K, Ma Y, Yang F. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013. PMID: 24187501; PMCID: PMC3810446.
Copy Download .nbib Format: NLM
Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis.

Oncotarget

Yang L, Guo G, Sun L, Li C, Zhang H.
PMID: 28938689
Oncotarget. 2017 Mar 30;8(35):59867-59877. doi: 10.18632/oncotarget.16729. eCollection 2017 Aug 29.

BACKGROUND: Ovarian neoplasm is a kind of high risky cancer among female. This paper assessed the efficacy and safety of twelve therapies and figured out the superior chemotherapeutic drug for ovarian cancer through network meta-analysis (NMA).METHOD: Eligible randomized controlled...

Cite
Yang L, Guo G, Sun L, et al. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget. 2017;8(35):59867-59877doi: 10.18632/oncotarget.16729.
Yang, L., Guo, G., Sun, L., Li, C., & Zhang, H. (2017). Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget, 8(35), 59867-59877. https://doi.org/10.18632/oncotarget.16729
Yang, Lili, et al. "Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis." Oncotarget vol. 8,35 (2017): 59867-59877. doi: https://doi.org/10.18632/oncotarget.16729
Yang L, Guo G, Sun L, Li C, Zhang H. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget. 2017 Mar 30;8(35):59867-59877. doi: 10.18632/oncotarget.16729. eCollection 2017 Aug 29. PMID: 28938689; PMCID: PMC5601785.
Copy Download .nbib Format: NLM
Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report.

Surgical case reports

Aoyagi K, Kizaki J, Isobe T, Akagi Y.
PMID: 26943449
Surg Case Rep. 2015 Dec;1(1):125. doi: 10.1186/s40792-015-0126-1. Epub 2015 Dec 24.

A 69-year-old man was referred to our institution for treatment of gastric cancer. Type 2 gastric cancer was found on the anterior wall of the lower body of the stomach.The patient underwent distal gastrectomy, D2 lymph node dissection, and...

Cite
Aoyagi K, Kizaki J, Isobe T, et al. Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surg Case Rep. 2015;1(1):125doi: 10.1186/s40792-015-0126-1.
Aoyagi, K., Kizaki, J., Isobe, T., & Akagi, Y. (2015). Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surgical case reports, 1(1), 125. https://doi.org/10.1186/s40792-015-0126-1
Aoyagi, Keishiro, et al. "Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report." Surgical case reports vol. 1,1 (2015): 125. doi: https://doi.org/10.1186/s40792-015-0126-1
Aoyagi K, Kizaki J, Isobe T, Akagi Y. Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surg Case Rep. 2015 Dec;1(1):125. doi: 10.1186/s40792-015-0126-1. Epub 2015 Dec 24. PMID: 26943449; PMCID: PMC4690825.
Copy Download .nbib Format: NLM
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

NPJ breast cancer

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
PMID: 28948212
NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved pathologic complete response...

Cite
Wolf DM, Yau C, Sanil A, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017;3:31doi: 10.1038/s41523-017-0025-7.
Wolf, D. M., Yau, C., Sanil, A., Glas, A., Petricoin, E., Wulfkuhle, J., Severson, T. M., Linn, S., Brown-Swigart, L., Hirst, G., Buxton, M., DeMichele, A., Hylton, N., Symmans, F., Yee, D., Paoloni, M., Esserman, L., Berry, D., Rugo, H., Olopade, O., & van 't Veer, L. (2017). DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ breast cancer, 331. https://doi.org/10.1038/s41523-017-0025-7
Wolf, Denise M, et al. "DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial." NPJ breast cancer vol. 3 (2017): 31. doi: https://doi.org/10.1038/s41523-017-0025-7
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017. PMID: 28948212; PMCID: PMC5572474.
Copy Download .nbib Format: NLM
Metastatic anal sac carcinoma with hypercalcaemia and associated hypertrophic osteopathy in a dog.

Open veterinary journal

Giuliano A, Salgüero R, Dobson J.
PMID: 26623365
Open Vet J. 2015;5(1):48-51. Epub 2015 May 07.

A seven-year-old male neutered Irish setter was treated for a metastatic anal sac adenocarcinoma (ASAC) and hypercalcaemia by complete surgical excision of the primary tumour and partial excision of the sublumbar lymph nodes. Further enlargement of the sublumbar lymph...

Cite
Giuliano A, Salgüero R, Dobson J. Metastatic anal sac carcinoma with hypercalcaemia and associated hypertrophic osteopathy in a dog. Open Vet J. 2015;5(1):48-51
Giuliano, A., Salgüero, R., & Dobson, J. (2015). Metastatic anal sac carcinoma with hypercalcaemia and associated hypertrophic osteopathy in a dog. Open veterinary journal, 5(1), 48-51.
Giuliano, A, et al. "Metastatic anal sac carcinoma with hypercalcaemia and associated hypertrophic osteopathy in a dog." Open veterinary journal vol. 5,1 (2015): 48-51.
Giuliano A, Salgüero R, Dobson J. Metastatic anal sac carcinoma with hypercalcaemia and associated hypertrophic osteopathy in a dog. Open Vet J. 2015;5(1):48-51. Epub 2015 May 07. PMID: 26623365; PMCID: PMC4629575.
Copy Download .nbib Format: NLM
Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma.

Journal of thoracic disease

Song Z.
PMID: 25589977
J Thorac Dis. 2014 Dec;6(12):1808-12. doi: 10.3978/j.issn.2072-1439.2014.11.18.

OBJECTIVE: For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been established in second- or further-line settings. The aim of this study was to evaluate the feasibility and safety of paclitaxel plus carboplatin in advanced thymic carcinoma as...

Cite
Song Z. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. J Thorac Dis. 2014;6(12):1808-12doi: 10.3978/j.issn.2072-1439.2014.11.18.
Song, Z. (2014). Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. Journal of thoracic disease, 6(12), 1808-12. https://doi.org/10.3978/j.issn.2072-1439.2014.11.18
Song, Zhengbo. "Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma." Journal of thoracic disease vol. 6,12 (2014): 1808-12. doi: https://doi.org/10.3978/j.issn.2072-1439.2014.11.18
Song Z. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. J Thorac Dis. 2014 Dec;6(12):1808-12. doi: 10.3978/j.issn.2072-1439.2014.11.18. PMID: 25589977; PMCID: PMC4283302.
Copy Download .nbib Format: NLM
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.

South Asian journal of cancer

Dessai SB, Chakraborty S, Babu TV, Nayanar S, Bhattacharjee A, Jones J, Balasubramanian S, Patil VM.
PMID: 27275450
South Asian J Cancer. 2016 Apr-Jun;5(2):63-6. doi: 10.4103/2278-330X.181629.

OBJECTIVE: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to examine the toxicity and response rates...

Cite
Dessai SB, Chakraborty S, Babu TV, et al. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer. 2016;5(2):63-6doi: 10.4103/2278-330X.181629.
Dessai, S. B., Chakraborty, S., Babu, T. V., Nayanar, S., Bhattacharjee, A., Jones, J., Balasubramanian, S., & Patil, V. M. (2016). Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian journal of cancer, 5(2), 63-6. https://doi.org/10.4103/2278-330X.181629
Dessai, S B, et al. "Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin." South Asian journal of cancer vol. 5,2 (2016): 63-6. doi: https://doi.org/10.4103/2278-330X.181629
Dessai SB, Chakraborty S, Babu TV, Nayanar S, Bhattacharjee A, Jones J, Balasubramanian S, Patil VM. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer. 2016 Apr-Jun;5(2):63-6. doi: 10.4103/2278-330X.181629. PMID: 27275450; PMCID: PMC4873699.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Hulin A, Chatelut E, Royer B, Le Guellec C.
PMID: 27392981
Therapie. 2010 May-Jun;65(3):157-62. doi: 10.2515/therapie/2010021.

Carboplatin is an anticancer agent widely used in different types of cancer in adults and paediatrics patients. Carboplatin undergoes an high protein binding percentage in plasma and presents a major hematotoxicity. Some studies determined unbound and bound platin concentrations...

Cite
Hulin A, Chatelut E, Royer B, et al. Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine. [Not Available]. Therapie. 2010;65(3):157-62doi: 10.2515/therapie/2010021.
Hulin, A., Chatelut, E., Royer, B., Le Guellec, C. (2010). Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine. [Not Available]. Therapie, 65(3), 157-62. https://doi.org/10.2515/therapie/2010021
Hulin, Anne, et al. "Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine." [Not Available]. Therapie vol. 65,3 (2010): 157-62. doi: https://doi.org/10.2515/therapie/2010021
Hulin A, Chatelut E, Royer B, Le Guellec C. Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine. [Not Available]. Therapie. 2010 May-Jun;65(3):157-62. doi: 10.2515/therapie/2010021. French. PMID: 27392981.
Copy Download .nbib Format: NLM
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?.

Journal of Cancer

Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K.
PMID: 25767606
J Cancer. 2015 Feb 23;6(4):360-6. doi: 10.7150/jca.11308. eCollection 2015.

PURPOSE: Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Furthermore, somatostatin (SST) receptors (SSTR1, 2A and B, 3, 4...

Cite
Domvri K, Bougiouklis D, Zarogoulidis P, et al. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. J Cancer. 2015;6(4):360-6doi: 10.7150/jca.11308.
Domvri, K., Bougiouklis, D., Zarogoulidis, P., Porpodis, K., Xristoforidis, M., Liaka, A., Eleutheriadou, E., Lampaki, S., Lazaridis, G., Organtzis, J., Kyriazis, G., Hohenforst-Schmidt, W., Tsirgogianni, K., Karavasilis, V., Baka, S., Darwiche, K., Freitag, L., Trakada, G., & Zarogoulidis, K. (2015). Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. Journal of Cancer, 6(4), 360-6. https://doi.org/10.7150/jca.11308
Domvri, Kalliopi, et al. "Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?." Journal of Cancer vol. 6,4 (2015): 360-6. doi: https://doi.org/10.7150/jca.11308
Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. J Cancer. 2015 Feb 23;6(4):360-6. doi: 10.7150/jca.11308. eCollection 2015. PMID: 25767606; PMCID: PMC4349876.
Copy Download .nbib Format: NLM
A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy.

Molecular and clinical oncology

Takatori E, Shoji T, Miura Y, Nagao M, Takada A, Nagasawa T, Omi H, Kagabu M, Honda T, Sugiyama T.
PMID: 25798254
Mol Clin Oncol. 2015 Mar;3(2):281-286. doi: 10.3892/mco.2015.484. Epub 2015 Jan 09.

There are currently no studies demonstrating the effects of palonosetron on delayed chemotherapy-induced nausea and vomiting (CINV) in gynecological cancer patients receiving chemotherapy with moderately emetogenic chemotherapeutic agents. We conducted a phase II clinical trial to assess the efficacy...

Cite
Takatori E, Shoji T, Miura Y, et al. A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol. 2015;3(2):281-286doi: 10.3892/mco.2015.484.
Takatori, E., Shoji, T., Miura, Y., Nagao, M., Takada, A., Nagasawa, T., Omi, H., Kagabu, M., Honda, T., & Sugiyama, T. (2015). A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Molecular and clinical oncology, 3(2), 281-286. https://doi.org/10.3892/mco.2015.484
Takatori, Eriko, et al. "A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy." Molecular and clinical oncology vol. 3,2 (2015): 281-286. doi: https://doi.org/10.3892/mco.2015.484
Takatori E, Shoji T, Miura Y, Nagao M, Takada A, Nagasawa T, Omi H, Kagabu M, Honda T, Sugiyama T. A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol. 2015 Mar;3(2):281-286. doi: 10.3892/mco.2015.484. Epub 2015 Jan 09. PMID: 25798254; PMCID: PMC4360756.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2092 entries